Schonfeld Strategic Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-36,643	Closed	-$364K	–	2099
2023 Q1	$364K	Buy	+36,643	New	+$259K	﹤0.01%	1291
2021 Q4	–	Sell	-28,800	Closed	-$253K	–	2101
2021 Q3	$253K	Sell	28,800 -2,194	-7%	-$20.1K	﹤0.01%	1625
2021 Q2	$351K	Buy	30,994 +15,588	+101%	+$187K	﹤0.01%	1375
2021 Q1	$182K	Sell	15,406 -18,248	-54%	-$210K	﹤0.01%	1537
2020 Q4	$232K	Sell	33,654 -74,446	-69%	-$523K	﹤0.01%	1286
2020 Q3	$801K	Sell	108,100 -29,500	-21%	-$191K	0.02%	763
2020 Q2	$574K	Buy	+137,600	New	+$503K	0.01%	763

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Schonfeld Strategic Advisors's ALDX Position: Q2 2023 in Review

Schonfeld Strategic Advisors sold out of Aldeyra Therapeutics (ALDX) in Q2 2023, closing a stake of 36,643 shares — an estimated $364K sold.

Schonfeld Strategic Advisors first reported a position in ALDX in Q2 2020 and held it in 7 quarters. The position peaked at $801K in Q3 2020. 119 funds tracked by Wall St. Rank hold ALDX as of Q2 2023.

Schonfeld Strategic Advisors reported no remaining Aldeyra Therapeutics position as of Q2 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 36,643 Aldeyra Therapeutics shares in Q2 2023, an estimated $364K.
Schonfeld Strategic Advisors first reported a position in Aldeyra Therapeutics in Q2 2020 and held it in 7 quarters.
Schonfeld Strategic Advisors's Aldeyra Therapeutics position peaked at $801K in Q3 2020.
119 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.